findmyKOL
Clinical trialNCT05450965RecruitingPhase 2Interventional

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

SponsorUniversity of Maryland, BaltimoreEnrollment37Small Cell Lung CarcinomaSmall-cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, United States

    Taofeek Owonikoko, MD, PhD →
    Recruiting
  • Upmc Hillman Cancer Center

    Pittsburgh, Pennsylvania, United States

    Active, not recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Onvansertib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Jul 2022
Primary completion
31 Aug 2027
Completion
30 Nov 2027
Last update posted
17 Dec 2025
Registered enrollment
37
Registry id
NCT05450965
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.